Case | HBS Case Collection | 2005 (Revised from original 2005 version)
by David S. Scharfstein and Darren R. Smart
Massachusetts General Hospital is considering selling its royalty interest in Enbrel, Amgen's blockbuster drug for the treatment of rheumatoid arthritis. In assessing whether to sell, and at what price, the hospital must determine its value to a potential buyer as well as its own value of the royalty income.
Keywords: Valuation; Price; Investment Return; Capital; Value; Revenue; Health Care and Treatment; Health Industry; Biotechnology Industry; Massachusetts;
Citation:
Scharfstein, David S., and Darren R. Smart. "Massachusetts General Hospital and the Enbrel Royalty." Harvard Business School Case 206-075, November 2005. (Revised from original November 2005 version.)
View Profile »View Publications »
Article | Journal of Economic Perspectives | Spring 2013
The Growth of Finance
Robin Greenwood and David S. Scharfstein
Keywords: Asset Management; Research; Finance; Mortgages; Financial Services Industry;
Mimeo | 2013
Concentration in Mortgage Lending, Refinancing Activity, and Mortgage Rates
David S. Scharfstein and Adi Sunderam
Keywords: Mortgages; Banking Industry; United States;
Working Paper | 2013
An Evaluation of Money Market Fund Reform Proposals
Samuel G. Hanson, David S. Scharfstein and Adi Sunderam